GLP-1s Are Not the End of Bariatric Surgery; They’re the Beginning of Better Obesity Care

The premise that GLP-1 receptor agonists are replacing bariatric surgery for weight management is not just oversimplified; it’s wrong.

1

GLP-1 receptor agonists are not replacing bariatric surgery but are part of a multimodal approach to obesity care.
2

The approval of oral GLP-1s like semaglutide and orforglipron expands treatment options for patients who prefer non-injection methods.
3

GLP-1s have increased patient engagement in obesity treatment, with one in eight Americans having tried these medications.
4

Bariatric surgery remains essential for patients who do not achieve sufficient weight loss with GLP-1s alone.
5

A comprehensive approach to obesity care requires understanding individual patient needs and utilizing various treatment modalities.

1